丹娜生物：向不特定合格投资者公开发行股票获批

Core Insights - The China Securities Regulatory Commission has approved Danaher's public offering of shares to unspecified qualified investors, highlighting its status as a national high-tech enterprise and a key player in the specialized "little giant" category [2] - Danaher reported a revenue of 116 million yuan and a net profit of 49.96 million yuan for the first half of 2025, marking a year-on-year growth of 29.55% [2] Research and Development - Danaher has established six core technology platforms in the in vitro diagnostics industry, leading to significant breakthroughs in key technical areas [3] - As of June 2025, 23.78% of the company's workforce is dedicated to R&D, with nearly 80% holding master's or doctoral degrees [3] - The company has obtained 90 domestic and international patents, including 46 invention patents, and has received multiple certifications for its medical devices [3] Product Portfolio - Danaher has developed a comprehensive product system to address the complex clinical scenarios of invasive fungal disease diagnosis, offering a one-stop diagnostic solution [4] - The product range includes five major series of diagnostic reagents and various automated diagnostic instruments, widely used in diagnosing invasive fungal diseases and antibiotic resistance [4] - The company has introduced innovative POCT products to meet grassroots medical needs and has established a unique "5G + fungal disease serology joint detection scheme" [4] Supply Chain Management - Danaher faced challenges in sourcing key raw materials for its enzyme kinetics series but has successfully navigated these issues through early planning and technical innovation [5] - The company holds a legal license for the use of existing stocks of horseshoe crab blood cells, ensuring stable supply for over five years [5] - Danaher has developed alternative products based on immunodiagnostic methodologies, effectively replacing traditional products without significant performance loss [5] Future Outlook - Danaher aims to further consolidate its technological advantages and expand production capacity, seizing industry opportunities to strengthen its global leadership position [6]